induces spontaneous humoral and cellular immune responses NY-ESO-1 is highly expressed in poor prognosis multiple myeloma and

[1]  Mark Shackleton,et al.  Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  J. McCluskey,et al.  Immunodominant CD4+ responses identified in a patient vaccinated with full-length NY-ESO-1 formulated with ISCOMATRIX adjuvant. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[3]  M. Monden,et al.  NY-ESO-1 Expression and Immunogenicity in Malignant and Benign Breast Tumors , 2004, Cancer Research.

[4]  Bart Barlogie,et al.  Genetics and Cytogenetics of Multiple Myeloma , 2004, Cancer Research.

[5]  R. Bataille,et al.  Single versus double autologous stem-cell transplantation for multiple myeloma. , 2003, The New England journal of medicine.

[6]  V. Reuter,et al.  Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer. , 2003, Cancer immunity.

[7]  Danila Valmori,et al.  Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. , 2003, Cancer immunity.

[8]  Yao-Tseng Chen,et al.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[9]  P. Roche,et al.  Identification of NY‐ESO‐1, MAGE‐1, and MAGE‐3 in head and neck squamous cell carcinoma , 2003, Head & neck.

[10]  F. Zhan,et al.  Continuous absence of metaphase-defined cytogenetic abnormalities, especially of chromosome 13 and hypodiploidy, ensures long-term survival in multiple myeloma treated with Total Therapy I: interpretation in the context of global gene expression. , 2003, Blood.

[11]  L. Terracciano,et al.  Expression of Cancer/Testis Tumor Associated Antigens in Cervical Squamous Cell Carcinoma , 2003, Oncology.

[12]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[13]  Angela Bachi,et al.  Identification of immunodominant regions among promiscuous HLA-DR-restricted CD4+ T-cell epitopes on the tumor antigen MAGE-3. , 2003, Blood.

[14]  A. Pinchera,et al.  Analysis of cancer/testis antigens in sporadic medullary thyroid carcinoma: expression and humoral response to NY-ESO-1. , 2003, The Journal of clinical endocrinology and metabolism.

[15]  C. Pellat-deceunynck,et al.  Tumour‐associated antigens in multiple myeloma , 2003, British journal of haematology.

[16]  B. Barlogie,et al.  Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization‐defined chromosome 13 deletion in multiple myeloma: early results of total therapy II , 2003, British journal of haematology.

[17]  Danila Valmori,et al.  Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. , 2002, The Journal of clinical investigation.

[18]  J. D. Vos,et al.  Comparison of gene expression profiling between malignant and normal plasma cells with oligonucleotide arrays , 2002, Oncogene.

[19]  R. Bataille,et al.  Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy. , 2002, Blood.

[20]  K. Tarte,et al.  Generation of polyclonal plasmablasts from peripheral blood B cells: a normal counterpart of malignant plasmablasts. , 2002, Blood.

[21]  John Crowley,et al.  Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. , 2002, Blood.

[22]  B. Barlogie,et al.  Predicting long‐term (≥ 5 years) event‐free survival in multiple myeloma patients following planned tandem autotransplants , 2002, British journal of haematology.

[23]  N. Hensel,et al.  Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. , 2001, Blood.

[24]  Alessandro Sette,et al.  Identification of New Epitopes from Four Different Tumor-Associated Antigens: Recognition of Naturally Processed Epitopes Correlates with HLA-A∗0201-Binding Affinity1 , 2001, The Journal of Immunology.

[25]  N. Altorki,et al.  Immunohistochemical analysis of NY‐ESO‐1 antigen expression in normal and malignant human tissues , 2001, International journal of cancer.

[26]  S. Rosenberg,et al.  CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Steven A. Rosenberg,et al.  Induction of Tumor-Reactive Cytotoxic T-Lymphocytes Using a Peptide from NY-ESO-1 Modified at the Carboxy-terminus to Enhance HLA-A2.1 Binding Affinity and Stability in Solution , 2001, Journal of immunotherapy.

[28]  D. Jäger,et al.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  D. Speiser,et al.  Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. , 2000, Cancer research.

[30]  Yao-Tseng Chen,et al.  SEREX analysis of gastric cancer antigens , 2000, Cancer Chemotherapy and Pharmacology.

[31]  V. Cerundolo,et al.  Identification of NY-ESO-1 Peptide Analogues Capable of Improved Stimulation of Tumor-Reactive CTL1 , 2000, The Journal of Immunology.

[32]  B. Barlogie,et al.  Results of high-dose therapy for 1000 patients with multiple myeloma: durable complete remissions and superior survival in the absence of chromosome 13 abnormalities. , 2000, Blood.

[33]  F. Gudat,et al.  NY-ESO-1 tumour associated antigen is a cytoplasmic protein detectable by specific monoclonal antibodies in cell lines and clinical specimens , 2000, British Journal of Cancer.

[34]  D. Jäger,et al.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  D. Jäger,et al.  Antigens recognized by autologous antibody in patients with renal‐cell carcinoma , 1999, International journal of cancer.

[36]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[37]  D. Jäger,et al.  Humoral immune responses of cancer patients against “Cancer‐Testis” antigen NY‐ESO‐1: Correlation with clinical events , 1999 .

[38]  M. Boccadoro,et al.  Dose-intensive melphalan with stem cell support (MEL100) is superior to standard treatment in elderly myeloma patients. , 1999, Blood.

[39]  F. Brasseur,et al.  Genes encoding tumor-specific antigens are expressed in human myeloma cells. , 1999, Blood.

[40]  Ferry Ossendorp,et al.  CD4 T Cells and Their Role in Antitumor Immune Responses , 1999, The Journal of experimental medicine.

[41]  A. Eggermont,et al.  Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.

[42]  D. Pardoll,et al.  The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.

[43]  Yao-Tseng Chen,et al.  Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Lloyd J. Old,et al.  A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens , 1998, The Journal of experimental medicine.

[45]  Lloyd J. Old,et al.  New Paths in Human Cancer Serology , 1998, The Journal of experimental medicine.

[46]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[47]  S. Singhal,et al.  Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment , 1997, Bone Marrow Transplantation.

[48]  B. Barlogie,et al.  Unique role of cytogenetics in the prognosis of patients with myeloma receiving high-dose therapy and autotransplants. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  Yao-Tseng Chen,et al.  A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[50]  B. Barlogie,et al.  Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.

[51]  J. Rossi,et al.  A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .

[52]  B. Barlogie,et al.  Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. , 1995, Blood.

[53]  K. Sakaguchi,et al.  Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. , 1995, Journal of immunology.

[54]  A. Sette,et al.  Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.

[55]  K. Sakaguchi,et al.  Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes , 1994, The Journal of experimental medicine.

[56]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[57]  P. Coulie,et al.  The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas , 1993, The Journal of experimental medicine.

[58]  B. Barlogie,et al.  Treatment of multiple myeloma. , 2004, Blood.

[59]  A. Simpson,et al.  The cancer/testis genes: review, standardization, and commentary. , 2004, Cancer immunity.

[60]  Yao-Tseng Chen,et al.  NY-ESO-1 mRNA expression and immunogenicity in advanced prostate cancer. , 2003, Cancer immunity.

[61]  J. Teruya-Feldstein,et al.  Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7, and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. , 2003, Cancer immunity.

[62]  B. Barlogie,et al.  Early results of total therapy II in multiple myeloma: Implications of cytogenetics and FISH , 2002, International journal of hematology.

[63]  H. Johnsen,et al.  Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Nordic Myeloma Study Group. , 2000, Blood.

[64]  B. Barlogie,et al.  Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.